DeCure for Bronchiectasis with or without elevated sweat chloride 3
DeCure's autonomous Respiratory AI scientist is researching a drug-repurposing hypothesis for bronchiectasis with or without elevated sweat chloride 3 — screening already-approved drugs against its 3-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleBronchiectasis with or without elevated sweat chloride 3 maps to a 3-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for bronchiectasis with or without elevated sweat chloride 3 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
solute carrier family 4 member 1 (Diego blood group) (SLC4A1) — SLC4A1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet clrdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 7UZ3 · 2.35 Å · ligand CHOLESTEROL (CLR). Experimental structure, not a prediction.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
JAMA · 1959 · 57 citations
CONSIDERATION OF CYSTIC FIBROSIS IN ADULTS, WITH A STUDY OF SWEAT ELECTROLYTE VALUES
AbstractThe sweat test used in the diagnosis of cystic fibrosis consists of the determination of chloride and sodium concentrations. In this study the sweat was collected on small cellulose sponges sealed against certain cleansed areas of skin. The test was applied to 34 persons a total of 89 times to determine its reliability. In 96 subjects assumed to be free from all known forms of cystic fibrosis, the chloride content of sweat never exceeded 70 mEq. per liter; in 6 patients with cystic fibrosis it always exceeded 75 mEq. per liter. Abnormal values of 69 mEq. per liter of chloride or 79 or more mEq. per liter of sodium were found in 8 of 25 patients with cylindrical bronchiectasis. Evidence indicates that cystic fibrosis is a general dysfunction of exocrine glands and that it should be considered among the possible causes of chronic endobronchial disease.
Revista do Hospital das Clínicas · 2003 · 11 citations · open access
Cystic fibrosis with normal sweat chloride concentration: case report
AbstractCystic fibrosis is a genetic disease usually diagnosed by abnormal sweat testing. We report a case of an 18-year-old female with bronchiectasis, chronic P. aeruginosa infection, and normal sweat chloride concentrations who experienced rapid decrease of lung function and clinical deterioration despite treatment. Given the high suspicion of cystic fibrosis, broad genotyping testing was performed, showing a compound heterozygous with deltaF508 and 3849+10 kb C-->T mutations, therefore confirming cystic fibrosis diagnosis. Although the sweat chloride test remains the gold standard for the diagnosis of cystic fibrosis, alternative diagnostic tests such as genotyping and electrophysiologic measurements must be performed if there is suspicion of cystic fibrosis, despite normal or borderline sweat chloride levels.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
